<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03303963</url>
  </required_header>
  <id_info>
    <org_study_id>DRIA2014-326</org_study_id>
    <nct_id>NCT03303963</nct_id>
  </id_info>
  <brief_title>DIAgnostics for Multidrug Resistant Tuberculosis in Africa</brief_title>
  <acronym>DIAMA</acronym>
  <official_title>Culture Free Diagnosis and Follow-up of Multidrug Resistant Tuberculosis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dissou AFFOLABI</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rwanda Biomedical Center (RBC), Kigali, Rwanda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Tuberculosis Reference Laboratory Bamenda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jimma University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Service de Pneumophtisiologie, Hôpital Ignace Deen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of the Sciences, Techniques and Technologies of Bamako</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Damien Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cheikh Anta Diop University, Senegal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genoscreen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratoire de Référence des Mycobactéries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent advances in molecular diagnostics of tuberculosis, especially the GeneXpert&#xD;
      Mycobacterium tuberculosis/Rifampicin test have reduced the time to diagnose Rifampicin&#xD;
      Resistant Tuberculosis (RR-TB) but only rifampicin resistance is diagnosed, leading to&#xD;
      presumptive diagnosis of resistance to isoniazid and maybe other drugs. Thus in low and&#xD;
      middle income countries, most drug sensitivity testing relies on phenotypic drug resistance&#xD;
      testing, which takes up to 4 months. In addition, currently, culture on monthly sputum&#xD;
      samples is recommended by the World Health Organization for follow-up of Rifampicin Resistant&#xD;
      Tuberculosis patients under treatment. Unfortunately, culture is often not locally available&#xD;
      and samples need to be transported from field to culture laboratories. The associated&#xD;
      transport delays lead to high rates of contamination and false negative culture, particularly&#xD;
      in laboratories in low resource settings. Many gaps for the diagnosis and management of RR-TB&#xD;
      patients still need to be addressed and the DIAMA project (DIAgnostics for Multidrug&#xD;
      resistant tuberculosis in Africa) study aims to address some of them.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed DIAMA (DIAgnostics for Multidrug resistant tuberculosis in Africa) study aims to&#xD;
      address current gaps in the diagnosis and management of patients with Multi-Drug-Resistant&#xD;
      (MDR) tuberculosis. Building on existing networks and research collaborations previously&#xD;
      funded by the European &amp; Developing Countries Clinical Trials Partnership (EDCTP), this&#xD;
      project involved partners in West, Central, and East Africa. It aims to evaluate and&#xD;
      implement rapid and accurate molecular tests for several anti Tuberculosis drugs, to replace&#xD;
      the current dependency on phenotypic drug resistance testing, which takes up to 4 months and&#xD;
      is technically so demanding that few laboratories can perform it correctly.&#xD;
&#xD;
      The project builds on the continuous surveillance of Tuberculosis retreatment patients for&#xD;
      rifampicin resistance. Two African partners (Benin and Rwanda) with advanced molecular&#xD;
      laboratories are establishing reference laboratories for the 'Deeplex' assay, a novel&#xD;
      multiplex deep sequencing-based drug resistance diagnostic platform that simultaneously&#xD;
      provides sequence information of genes that confer resistance to several key anti&#xD;
      tuberculosis drugs. Partners are recruiting all patients with rifampicin resistant&#xD;
      Tuberculosis, and a subset of those with rifampicin sensitive Tuberculosis. In a first phase,&#xD;
      sputum will be shipped for the Deeplex assay, for comparison against phenotypic DST, the&#xD;
      reference method for detecting resistance to 1st and 2nd line drugs. In addition, since Whole&#xD;
      Genome Sequencing is the &quot;reference&quot; of molecular tests, Deeplex assay will also be validated&#xD;
      again this test. In a second phase, Cepheid 2nd line Xpert and Molbio Truenat test, two&#xD;
      'lower tech' tests at the last stages of laboratory validations, will also be validated. The&#xD;
      Cepheid Xpert 2nd line cartridge can be implemented in existing Xpert machines used for the&#xD;
      Xpert MTB/Rif assays. These tests will be compared versus the Deeplex assay and versus WGS&#xD;
&#xD;
      Using the latest advances in DataTocare software developed by one of the project partners,&#xD;
      molecular results will be communicated in real time to the National Tuberculosis Programmes,&#xD;
      so that Multi Drug Resistant Tuberculosis patients can swiftly start appropriate treatment.&#xD;
      The added-value of this system will be evaluated as a pilot study in some sites.&#xD;
&#xD;
      Lastly, once patients have initiated MDR treatment, they will be monitored for treatment&#xD;
      success by faster alternative approaches to the WHO recommended monthly cultures: serial&#xD;
      sputum samples will have Fluorescein DiAcetate (FDA) vital stain microscopy, measurement of&#xD;
      the bacterial load using the Xpert MTB/Rif as well as precursor of ribosomal RNA measurement&#xD;
      (pre-rRNA).&#xD;
&#xD;
      Together, these advances are expected to dramatically improve the currently dismal prognosis&#xD;
      of MDR-TB in health systems in resource-poor settings.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 4, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of Deeplex test</measure>
    <time_frame>4 years</time_frame>
    <description>Concordance between phenotypic Drug Susceptibility Test, WGS and Deeplex results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validation of GeneXpert 2nd line</measure>
    <time_frame>4 years</time_frame>
    <description>Concordance between WGS, Deeplex results and GeneXpert 2nd line results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validation of MolBio TrueNat for INH, FQ and BDQ</measure>
    <time_frame>4 years</time_frame>
    <description>Concordance between WGS, Deeplex results and MolBioTrueNat results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validation of FDA microscopy</measure>
    <time_frame>4 years</time_frame>
    <description>Concordance between Culture results and FDA microscopy results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validation of GeneXpert Ct value</measure>
    <time_frame>4 years</time_frame>
    <description>Concordance between Culture results and GeneXpert Ct value results</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimation of proportion of additional resistance in patients resistant to Rifampicin</measure>
    <time_frame>4 years</time_frame>
    <description>Evaluation to be done with the Deeplex test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of the association of specific mutations against some drugs with programmatic treatment outcome</measure>
    <time_frame>4 years</time_frame>
    <description>Evaluation to be done with the Deeplex test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the add value of Connectivity system in the management of Multi Drug Resistant-Tuberculosis patients</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation to be done with Data2Care connectivity system</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2840</enrollment>
  <condition>Tuberculosis, Multidrug-Resistant</condition>
  <arm_group>
    <arm_group_label>Rifampicin resistant and susceptible patients</arm_group_label>
    <description>Study 1: Patients detected positive by the GeneXpert Mycobacterium tuberculosis/Rifampicin (susceptible and resistant to rifampicin)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rifampicin resistant patients</arm_group_label>
    <description>Study 2: Follow up of the rifampicin resistant patients included in the study 1 during their treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line</intervention_name>
    <description>Improvement of the diagnosis of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to diagnose Tuberculosis resistance to 1st and 2nd line drugs through novel molecular multiplex assays (Study 1) by:&#xD;
Validating the Deeplex test and establish a network for shipment of sputum samples in ethanol to regional reference laboratories (Study 1 - phase 1)&#xD;
Validating the Molbio Truenat test as a point of care test (Study 1 - phase 2)&#xD;
Validating the Cepheid GeneXpert 2nd line cartridge at the district level (Study 1 -phase2)</description>
    <arm_group_label>Rifampicin resistant and susceptible patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis</intervention_name>
    <description>Improvement of the management of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to set up alternative culture-free approaches for the monitoring of patients' response to Multi Drug Resistant-Tuberculosis treatment (Study 2), with:&#xD;
FDA microscopy&#xD;
Measurement of bacterial load by following Cycle threshold (Ct) values in GeneXpert Mycobacterium tuberculosis/Rifampicin&#xD;
Measurement of pre-rRNA synthesis</description>
    <arm_group_label>Rifampicin resistant patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sputum.&#xD;
&#xD;
      At the enrolment, three samples (spot-overnight-spot) will be collected for the comparison of&#xD;
      phenotypic results against molecular results.&#xD;
&#xD;
      During the treatment, two monthly samples (overnight-spot) will be collected for the&#xD;
      comparison of culture result against FDA Microscopy and GeneXpert Ct values.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Two multi center observational studies will be conducted:&#xD;
&#xD;
        Study 1: Cross sectional study for Tuberculosis(TB) cases aged ≥ 15 (all Rifampicin&#xD;
        resistant (RR) ones (new cases or retreatment patients) and equal number of Rifampicin&#xD;
        sensitive retreatment patients from the same country) with comparison of TB resistance&#xD;
        diagnostic test performance at baseline. There are 2 phases in this project; phase 1 is the&#xD;
        comparison of Deeplex results against the phenotypic results and WGS (Gold standard), phase&#xD;
        2 is the comparison of MolBio TrueNat and GeneXpert 2nd generation results against Deeplex&#xD;
        and WGS (gold standard).&#xD;
&#xD;
        Study 2: Cohort study of RR-TB patients (recruited in Study 1) under treatment with&#xD;
        comparison of the performance of FDA and GeneXpert compared to solid culture&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Being ≥ 15 year old&#xD;
&#xD;
          -  Having a positive test on GeneXpert (M. tuberculosis) with or without resistance&#xD;
             detected to rifampicin&#xD;
&#xD;
          -  Willing and able to provide written informed consent, or for minors: assent from and&#xD;
             consent from a legal representative&#xD;
&#xD;
        Exclusion Criteria: None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dissou AFFOLABI, MD, MSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratoire de Référence des Mycobactéries</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Tropical Medecine</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre National Hospitalier Universitaire de Pneumo-Phtisiologie de Cotonou</name>
      <address>
        <city>Cotonou</city>
        <state>Atlantique/Littoral</state>
        <zip>01BP321</zip>
        <country>Benin</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Tuberculosis Reference Laboratory Bamenda</name>
      <address>
        <city>Bamenda</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut National de Recherche Biomédicale (INRB)</name>
      <address>
        <city>Kinshasa</city>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jimma University</name>
      <address>
        <city>Jīma</city>
        <country>Ethiopia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumophtisiologie, Hôpital Ignace Deen, Conakry</name>
      <address>
        <city>Conakry</city>
        <country>Guinea</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Université des Sciences, des Techniques et des Technologies de Bamako, SEREFO</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Damien Fundation</name>
      <address>
        <city>Ibadan</city>
        <country>Nigeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rwanda Biomedical Center (RBC)</name>
      <address>
        <city>Kigali</city>
        <country>Rwanda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Université Cheick Anta Diop (UCAD)</name>
      <address>
        <city>Dakar</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Benin</country>
    <country>Cameroon</country>
    <country>Congo, The Democratic Republic of the</country>
    <country>Ethiopia</country>
    <country>Guinea</country>
    <country>Mali</country>
    <country>Nigeria</country>
    <country>Rwanda</country>
    <country>Senegal</country>
  </location_countries>
  <reference>
    <citation>Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010 Sep 9;363(11):1005-15. doi: 10.1056/NEJMoa0907847. Epub 2010 Sep 1.</citation>
    <PMID>20825313</PMID>
  </reference>
  <results_reference>
    <citation>Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, Narita M, Penã JM, Ponce-de-Leon A, Seung KJ, Shean K, Sifuentes-Osornio J, Van der Walt M, Van der Werf TS, Yew WW, Menzies D; Collaborative Group for Meta-analysis of Individual Patient Data in MDR-TB. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis. 2014 Nov 15;59(10):1364-74. doi: 10.1093/cid/ciu619. Epub 2014 Aug 5.</citation>
    <PMID>25097082</PMID>
  </results_reference>
  <results_reference>
    <citation>Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, Rieder HL. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014 Oct;18(10):1180-7. doi: 10.5588/ijtld.14.0100.</citation>
    <PMID>25216831</PMID>
  </results_reference>
  <results_reference>
    <citation>Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, Hanki Y, Van Deun A. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014 Oct;18(10):1188-94. doi: 10.5588/ijtld.13.0075.</citation>
    <PMID>25216832</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010 Sep 1;182(5):684-92. doi: 10.1164/rccm.201001-0077OC. Epub 2010 May 4.</citation>
    <PMID>20442432</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 24, 2017</study_first_submitted>
  <study_first_submitted_qc>October 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2017</study_first_posted>
  <last_update_submitted>July 22, 2021</last_update_submitted>
  <last_update_submitted_qc>July 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Laboratoire de Référence des Mycobactéries</investigator_affiliation>
    <investigator_full_name>Dissou AFFOLABI</investigator_full_name>
    <investigator_title>Professor (Deputy Head of the Laboratory)</investigator_title>
  </responsible_party>
  <keyword>culture-free</keyword>
  <keyword>tuberculosis</keyword>
  <keyword>multidrug resistant</keyword>
  <keyword>diagnosis</keyword>
  <keyword>follow-up</keyword>
  <keyword>africa</keyword>
  <keyword>molecular tools</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/63/NCT03303963/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

